The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects

被引：0
|
作者：
Bo Tan
Yi-Fan Zhang
Xiao-Yan Chen
Xiao-Hua Zhao
Guo-Xin Li
Da-Fang Zhong
机构：
[1] Chinese Academy of Sciences,Shanghai Institute of Materia Medica
[2] Liaoning University of Traditional Chinese Medicine,Departmant of Clinical Pharmacology, The Second Affiliated Hospital
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
Glipizide; Genetic polymorphism; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：145 / 151
页数：6
相关论文
共 50 条
  • [41] Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects
    Liu, Shuaibing
    Yao, Xia
    Tao, Jun
    Zhao, Shiyu
    Sun, Suke
    Wang, Suyun
    Tian, Xin
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (08): : 1030 - 1043
  • [42] Effects of mutations in CYP2C9 and CYP2C19 genes on phenytoin dose
    Kijsanayotin, Pornpimol
    Cloyd, James C.
    Leppik, Ilo E.
    Birnbaum, Angela K.
    Prassitisopin, Baralee
    Ramsay, R. Eugene
    Rarick, John O.
    Mishra, Usha
    White, James R.
    Marino, Susan E.
    Conway, Jeannine M.
    Oetting, William S.
    NEUROLOGY, 2007, 68 (12) : A212 - A212
  • [43] Implication of genetic polymorphisms in CYP2C9 and CYP2C19 on drug metabolism in isolated cryopreserved human hepatocytes
    Tolondo, Roberto
    Brown, Caitlin
    Heyward, Scott
    DRUG METABOLISM REVIEWS, 2010, 42 : 262 - 262
  • [44] Cytochrome p450 CYP2C9 and CYP2C19 genetic polymorphisms in croatian children with epilepsy
    Gjergja, R.
    Cvitanovic-Sojat, L.
    Bielen, L.
    Sojat, T.
    Stefanovic, M.
    EPILEPSIA, 2006, 47 : 182 - 183
  • [45] Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy Subjects
    Yoo, H-D
    Park, S-A
    Cho, H-Y
    Lee, Y-B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (03) : 281 - 284
  • [46] EFFECTS OF CYP2C19 HAPLOTYPE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF OMEPRAZOLE
    Bae, J. W.
    Choi, C., I
    Kim, M. J.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 79 - 80
  • [47] The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
    Mamiya, K
    Ieiri, I
    Shimamoto, J
    Yukawa, E
    Imai, J
    Ninomiya, H
    Yamada, H
    Otsubo, K
    Higuchi, S
    Tashiro, N
    EPILEPSIA, 1998, 39 (12) : 1317 - 1323
  • [48] Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response
    Nastasi-Catanese, J. A.
    Padilla-Gutierrez, J. R.
    Valle, Y.
    Ortega-Gutierrez, F.
    Gallegos-Arreola, M. P.
    Figuera, L. E.
    GENETICS AND MOLECULAR RESEARCH, 2013, 12 (04) : 4413 - 4421
  • [49] Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms
    Hung, CC
    Lin, CJ
    Chen, CC
    Chang, CJ
    Liou, HH
    THERAPEUTIC DRUG MONITORING, 2004, 26 (05) : 534 - 540
  • [50] Effects of combined CYP2C9 and 2C19 polymorphism on the pharmacokinetics of glibenclamide in Chinese subjects.
    Yin, OQ
    Tomlinson, B
    Chow, MS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P23 - P23
12345